Edition:
United States

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

4.35USD
1:44pm EDT
Change (% chg)

$-0.30 (-6.45%)
Prev Close
$4.65
Open
$4.70
Day's High
$4.70
Day's Low
$4.35
Volume
50,366
Avg. Vol
103,817
52-wk High
$8.60
52-wk Low
$3.60

Chart for

About

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $279.48
Shares Outstanding(Mil.): 60.10
Dividend: --
Yield (%): --

Financials

  ARDX.OQ Industry Sector
P/E (TTM): -- 213.33 32.89
EPS (TTM): -1.87 -- --
ROI: -59.67 -3.69 13.14
ROE: -59.97 -5.73 15.15

BRIEF-Ardelyx Announces Pricing Of Public Offering Of Common Stock

* ARDELYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

May 22 2018

BRIEF-Ardelyx Announces Proposed Public Offering Of Common Stock

* ARDELYX INC - STARTED UNDERWRITTEN PUBLIC OFFERING OF UP TO $50 MLN OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

May 21 2018

BRIEF-Ardelyx Reports Qtrly Loss Per Share $0.36

* ARDELYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

May 08 2018

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

* KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​

Mar 19 2018

BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21

* ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS

Mar 14 2018

Earnings vs. Estimates